Ketimine reductase mu-crystallin

BE0000104ProteinHumansCRYM

Catalyzes the NAD(P)H-dependent reduction of imine double bonds of a number of cyclic ketimine substrates, including sulfur-containing cyclic ketimines (PubMed:21332720, PubMed:25931162). It is acted on by 1 drug in DrugBank.

Gene name
CRYM
UniProtKB entry
Q14894Swiss-Prot
Cellular location
Cytoplasm
Residues / weight
314 residues · 33,775 Da
Also known as
1-piperideine-2-carboxylate/1-pyrroline-2-carboxylate reductase · 1.5.1.25 · NADP-regulated thyroid-hormone-binding protein · P2C/Pyr2C reductase · THBP

Resolves to

Protein
UniProtQ14894UniProt nameCRYM_HUMAN
Gene
HGNCHGNC:2418NCBI Gene1428GenBank1066343GeneCardsCRYM
Pharmacology
KEGGhsa:1428
Structure
PDB2I99
Drugs

What you can answer from here — as of September 07, 2019

1DrugApproved to experimental, with action, bond type and pharmacological action
Sign in
5GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
12+ReferencesStructured and connected to the statements they support
Sign in

Which compounds in development act on Ketimine reductase mu-crystallin, and which indications are they being tested in?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In